Manuscript DoiAdvance : 10.1093/ecco-jcc/jjv119 Journal of Crohn's and Colitis Access published July 4, 2015
Anti-TNF treatment with adalimumab induces changes in the microbiota of Crohn´s disease
rip t
Short tittle: Microbiota of CD patients with adalimumab. 5
Busquets,
David2,
*Mas-de-Xaxars,
Teresa1,
López-Siles, Mireia1, Martínez-Medina,
10
an
Garcia-Gil, Jesus L.1 and Aldeguer, Xavier2
us c
Margarita1, Bahí, Anna2, Sàbat, Miriam3, Louvriex, René2, Miquel-Cusachs, Josep Oriol2,
1
Laboratory of Molecular Microbiology, Department of Biology, University of Girona,
M
Catalonia, Spain; 2
Department of Gastroenterology, Hospital Dr. Josep Trueta, Girona, Catalonia, Spain;
3
CORRESPONDING AUTHOR:
ce
15
pt
ed
Gastroenterology Unit, Hospital Santa Caterina, Girona, Catalonia, Spain.
David Busquets
Ac
Department of Gastroenterology Hospital Universitari Doctor Josep Trueta (5th Floor)
Avinguda de França S/N
20
Girona, Catalonia ( Spain) Telephone: +34972940287
1 Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected]
Manuscript Doi : 10.1093/ecco-jcc/jjv119
Fax: +34972 94 02 91 e-Mail:[email protected]
rip t
25
ABSTRACT
us c
Background: The composition of the intestinal microbiota is altered in Crohn's disease (CD)
patients. The objective of this study was to evaluate the qualitative and quantitative changes in the microbiota of CD patients in three months of treatment with adalimumab (ADA), and determine whether or not these changes are produced towards the recovery of the normal,
an
30
healthy-like, microbiota.
M
Methods: The microbiota composition and the Faecalibacterium prausnitzii / Escherichia coli quantitative relationship as dysbiosis indicator, were studied at baseline (T0), one month (T1)
35
ed
and three months (T3) after starting treatment using a polymerase chain reaction–denaturing gradient gel electrophoresis (PCR-DGGE) of 16S rRNA gene fragments and quantitative PCR,
pt
respectively in colonic mucosal biopsies from fifteen CD patients and four healthy subjects. Results: T0 and T3 fingerprints were different in all patients; whereas T1 and T3 presented
ce
similar patterns. Recovered phylogroups were Firmicutes (79.1%), Bacteroides (12.5%), and Actinobacteria (6.25%). The prevalence of E. coli decreased along the treatment. Relative E. coli loads in CD samples were significantly reduced at every analysed step (T1 and T3)
Ac
40
(P
Anti-TNF treatment with adalimumab induces changes in the microbiota of Crohn´s disease
rip t
Short tittle: Microbiota of CD patients with adalimumab. 5
Busquets,
David2,
*Mas-de-Xaxars,
Teresa1,
López-Siles, Mireia1, Martínez-Medina,
10
an
Garcia-Gil, Jesus L.1 and Aldeguer, Xavier2
us c
Margarita1, Bahí, Anna2, Sàbat, Miriam3, Louvriex, René2, Miquel-Cusachs, Josep Oriol2,
1
Laboratory of Molecular Microbiology, Department of Biology, University of Girona,
M
Catalonia, Spain; 2
Department of Gastroenterology, Hospital Dr. Josep Trueta, Girona, Catalonia, Spain;
3
CORRESPONDING AUTHOR:
ce
15
pt
ed
Gastroenterology Unit, Hospital Santa Caterina, Girona, Catalonia, Spain.
David Busquets
Ac
Department of Gastroenterology Hospital Universitari Doctor Josep Trueta (5th Floor)
Avinguda de França S/N
20
Girona, Catalonia ( Spain) Telephone: +34972940287
1 Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected]
Manuscript Doi : 10.1093/ecco-jcc/jjv119
Fax: +34972 94 02 91 e-Mail:[email protected]
rip t
25
ABSTRACT
us c
Background: The composition of the intestinal microbiota is altered in Crohn's disease (CD)
patients. The objective of this study was to evaluate the qualitative and quantitative changes in the microbiota of CD patients in three months of treatment with adalimumab (ADA), and determine whether or not these changes are produced towards the recovery of the normal,
an
30
healthy-like, microbiota.
M
Methods: The microbiota composition and the Faecalibacterium prausnitzii / Escherichia coli quantitative relationship as dysbiosis indicator, were studied at baseline (T0), one month (T1)
35
ed
and three months (T3) after starting treatment using a polymerase chain reaction–denaturing gradient gel electrophoresis (PCR-DGGE) of 16S rRNA gene fragments and quantitative PCR,
pt
respectively in colonic mucosal biopsies from fifteen CD patients and four healthy subjects. Results: T0 and T3 fingerprints were different in all patients; whereas T1 and T3 presented
ce
similar patterns. Recovered phylogroups were Firmicutes (79.1%), Bacteroides (12.5%), and Actinobacteria (6.25%). The prevalence of E. coli decreased along the treatment. Relative E. coli loads in CD samples were significantly reduced at every analysed step (T1 and T3)
Ac
40
(P
